Physician profile
Joie D Russo
NPI 1619988532
$8,218.68
in general payments reported to CMS, 2019-2025
29 companies · $2,511 in 2025
The $2,511 reported for 2025 was more than what 95% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $559 · 2021: $1,263 · 2022: $1,287 · 2023: $1,116 · 2024: $959 · 2025: $2,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,387 · Consulting Fee: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.64 |
| Consulting Fee | $2,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,200.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $1,748.77 | 2019-2024 | Orilissa, Lo Loestrin Fe, Liletta |
| Pfizer INC. | $752.42 | 2022-2024 | |
| Therapeuticsmd, INC. | $488.35 | 2019-2022 | |
| Exeltis, USA INC. | $436.58 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $381.61 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $329.85 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $256.03 | 2021-2022 | |
| Evofem Biosciences, INC. | $219.37 | 2020-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $210.65 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $178.72 | 2021-2024 | Twirla |
| Hologic Sales and Service, LLC | $172.00 | 2021-2023 | Acessa Provu System |
| Organon LLC | $121.95 | 2024 | |
| Coopersurgical, INC. | $101.80 | 2020-2025 | |
| Allergan, INC. | $68.74 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $63.58 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.45 | 2025 | |
| Millicent US INC | $59.11 | 2025 | Intrarosa, Femlyv, Femring |
| Myriad Women'S Health, INC. | $58.63 | 2023 | Myrisk |
| Shield Therapeutics INC | $55.42 | 2023-2024 | Accrufer |
| Lupin INC. | $54.79 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $35.55 | 2021-2022 | |
| Sage Therapeutics, LLC | $31.44 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $29.76 | 2024 | Veozah |
| Lilly USA, LLC | $23.02 | 2023 | Emgality |
| Amag Pharmaceuticals, INC. | $22.81 | 2019 | |
| Duchesnay USA Incorporated | $19.46 | 2019 | |
| Vertical Pharmaceuticals, LLC | $18.81 | 2019 | |
| Boston Scientific Corporation | $18.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joie Russo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.